Despite early 2026 struggles with higher costs, is positioned for a rebound as it remains the largest commercial health insurer in the U.S..
remains a dominant force in the industry, recently striking drug pricing deals with the Trump Administration that have bolstered investor confidence.
: Its massive scale and pharmacy benefit manager (PBM) operations make it a staple for those seeking market stability. 5. Blue-Chip Logistics: Cencora (COR) medical stocks to buy
: With a projected 16% upside from analysts at U.S. News , Lilly is viewed as a high-speed growth stock despite broader pharma volatility. 2. Income & Stability: AbbVie (ABBV)
: Analysts at Yahoo Finance note its masterful navigation of "patent cliffs" as a key reason to hold. 3. Innovation & Robotics: Intuitive Surgical (ISRG) Despite early 2026 struggles with higher costs, is
Formerly known as AmerisourceBergen, is described as a "distribution growth juggernaut" in the pharmaceutical supply chain.
The healthcare sector has traditionally been a "defensive play" for investors, providing stability because people rarely cut back on essential medical care even during economic slumps. As of , the sector is showing improved momentum, with recent returns modestly outpacing the broader S&P 500 as the market rewards non-tech blue-chip stocks with strong forward prospects. Skyrizi and Rinvoq
: Its growth is currently driven by two blockbuster immunosuppressants, Skyrizi and Rinvoq , which are projected to reach peak sales exceeding those of its former lead drug, Humira.